ACC Scientific Session - American College of Cardiology Scientific Session

Sheldon Litwin, MD, a cardiologist at the Medical University of South Carolina, discussed the significant recent advances in anti-obesity drugs.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

The 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines recommend SGLT2 inhibitors for nearly all patients in cardiovascular practice.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

In an interview with Pharmacy Times, Anastasia Armbruster, PharmD, FACC, BCCP, discussed her presentation at the American College of Cardiology 2023 Scientific Session.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Pharmacists are essential health care team members who can be empowered to help initiate fixed-dose combinations, according to an expert panel at the American College of Cardiology 2023 Scientific Session.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Health care providers can manage “fake news” about statins, including their indications and misinformation regarding liver and kidney damage.

Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.

In addition to the hundreds of sessions and events, ACC has partnered with the World Heart Federation, bringing an international focus to the meeting.

Patients with atherosclerotic cardiovascular disease who were already receiving statin therapy had a reduction in adverse cardiovascular outcomes with earlier initiation of evolocumab.

American College of Cardiology President Edward Fry, MD, FACC, discussed what attendees can look forward to at the 2023 Scientific Sessions.

Dave Dixon, PharmD, discussed heart failure treatments in the pipeline and what he sees for the future of pharmacists in cardiovascular care.

With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.

Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.

Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.

Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

Health care professionals need to meet their patients at their health level and find a diet and medication regimen that works for them to best reduce the risk of cardiovascular events.

Pharmacy Times spoke with Craig Granowitz, MD, PhD, chief medical officer at Lexicon Pharmaceuticals, to learn more about sotagliflozin and new data being presented at the American College of Cardiology 2022 Scientific Sessions.

Pharmacy Times spoke with Orly Vardeny, PharmD, MS, a core investigator at the Center for Care Delivery and Outcomes Research in the US Department of Veterans Affairs, about pharmacists’ roles in managing pharmacotherapy disparities.